Literature DB >> 17056088

Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation.

Nicole L Yates1, Martha A Alexander-Miller.   

Abstract

Understanding how vaccinia virus (VV) generates immunity necessitates an appreciation for how this virus interacts with dendritic cells (DC), which are the most potent activators of naïve CD8(+) T cells. In order to optimally activate naïve CD8(+) T cells, DC must undergo maturation, during which costimulatory molecules are upregulated and cytokines are produced. In this report, we show that VV infection of immature murine bone marrow-derived DC (BMDC) failed to induce maturation. Similar results were obtained when CD8(+) DC were analyzed, a subset shown previously to be important in vivo in the generation of a vaccinia-specific response. The finding that VV infection of DC resulted in APC that were incapable of initiating T-cell activation was surprising given the previously reported role for direct presentation in the generation of anti-VV CD8(+) T-cell responses in mice. To address the potential mechanism responsible for direct presentation, we tested the hypothesis that previously matured DC were susceptible to vaccinia virus infection and could present newly synthesized VV-derived epitopes for CD8(+) T-cell activation. Our results show, that during VV infection of mature DC, threshold levels of viral protein are produced that promote T-cell activation. These results suggest that, even though VV cannot mature DC, previously matured DC exposed to VV can generate a VV-specific CD8(+) T-cell response providing a potential mechanism by which direct infection results in T-cell activation in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056088      PMCID: PMC1861836          DOI: 10.1016/j.virol.2006.09.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  71 in total

1.  Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells.

Authors:  P A MacAry; M Lindsay; M A Scott; J I Craig; J P Luzio; P J Lehner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo.

Authors:  C S Schmidt; M F Mescher
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

3.  A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

Authors:  A Bowie; E Kiss-Toth; J A Symons; G L Smith; S K Dower; L A O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

4.  Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells.

Authors:  N A Kukutsch; S Rossner; J M Austyn; G Schuler; M B Lutz
Journal:  J Invest Dermatol       Date:  2000-09       Impact factor: 8.551

5.  Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes.

Authors:  R Drillien; D Spehner; A Bohbot; D Hanau
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

6.  Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation.

Authors:  Julie M Curtsinger; Javier O Valenzuela; Pujya Agarwal; Debra Lins; Matthew F Mescher
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

7.  IL-1 beta induces dendritic cells to produce IL-12.

Authors:  A K Wesa; A Galy
Journal:  Int Immunol       Date:  2001-08       Impact factor: 4.823

8.  Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion.

Authors:  J Engelmayer; M Larsson; M Subklewe; A Chahroudi; W I Cox; R M Steinman; N Bhardwaj
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

9.  Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus.

Authors:  E A Kurt-Jones; L Popova; L Kwinn; L M Haynes; L P Jones; R A Tripp; E E Walsh; M W Freeman; D T Golenbock; L J Anderson; R W Finberg
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

10.  Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence.

Authors:  Julianne Stack; Ismar R Haga; Martina Schröder; Nathan W Bartlett; Geraldine Maloney; Patrick C Reading; Katherine A Fitzgerald; Geoffrey L Smith; Andrew G Bowie
Journal:  J Exp Med       Date:  2005-03-14       Impact factor: 14.307

View more
  13 in total

1.  Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vector.

Authors:  S Top; E Foulon; B Pignolet; M Deplanche; C Caubet; C Tasca; S Bertagnoli; G Meyer; G Foucras
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  B cell-specific expression of B7-2 is required for follicular Th cell function in response to vaccinia virus.

Authors:  Samira Salek-Ardakani; Youn Soo Choi; Mohammed Rafii-El-Idrissi Benhnia; Rachel Flynn; Ramon Arens; Stephen Shoenberger; Shane Crotty; Michael Croft; Shahram Salek-Ardakani
Journal:  J Immunol       Date:  2011-03-25       Impact factor: 5.422

Review 3.  Paramyxovirus activation and inhibition of innate immune responses.

Authors:  Griffith D Parks; Martha A Alexander-Miller
Journal:  J Mol Biol       Date:  2013-09-20       Impact factor: 5.469

4.  Autoantigens plus interleukin-10 suppress diabetes autoimmunity.

Authors:  Béla Dénes; István Fodor; William H R Langridge
Journal:  Diabetes Technol Ther       Date:  2010-08       Impact factor: 6.118

5.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  Regulation of maturation and activating potential in CD8+ versus CD8- dendritic cells following in vivo infection with vaccinia virus.

Authors:  Rama D Yammani; Sharmila Pejawar-Gaddy; Thaddeus C Gurley; Eric T Weimer; Elizabeth M Hiltbold; Martha A Alexander-Miller
Journal:  Virology       Date:  2008-06-30       Impact factor: 3.616

Review 7.  Proposed mechanisms of action for prostate cancer vaccines.

Authors:  Sean M Geary; Caitlin D Lemke; David M Lubaroff; Aliasger K Salem
Journal:  Nat Rev Urol       Date:  2013-02-12       Impact factor: 14.432

8.  Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.

Authors:  Susana Guerra; José Luis Nájera; José Manuel González; Luis A López-Fernández; Nuria Climent; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

9.  Persistent suppression of type 1 diabetes by a multicomponent vaccine containing a cholera toxin B subunit-autoantigen fusion protein and complete Freund's adjuvant.

Authors:  Béla Dénes; István Fodor; William H R Langridge
Journal:  Clin Dev Immunol       Date:  2013-11-11

10.  Functional paralysis of GM-CSF-derived bone marrow cells productively infected with ectromelia virus.

Authors:  Lidia Szulc-Dąbrowska; Justyna Struzik; Agnieszka Ostrowska; Maciej Guzera; Felix N Toka; Magdalena Bossowska-Nowicka; Małgorzata M Gieryńska; Anna Winnicka; Zuzanna Nowak; Marek G Niemiałtowski
Journal:  PLoS One       Date:  2017-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.